Hysterectomy Cancer Lawsuit Lawyers
Please note: Our law firm no longer accepts Morcellator cases.
Our law firm is reviewing hysterectomy cancer lawsuits or morcellator injury cases in all 50 states and Puerto Rico. If you or a loved one was diagnosed with cancer after a hysterectomy, contact a lawyer now for a free legal case consultation regarding a potential Hysterectomy Cancer Lawsuit. Use this form or call us toll-free at (888) 520-5202.
Hysterectomy Cancer Information
Matthews & Associates is reviewing hysterectomy cancer lawsuits for women who developed uterine sarcoma, leiomyosarcoma (LMS), or other aggressive cancers after laparoscopic surgery for a hysterectomy which used a morcellator. Most women experience uterine fibroids, benign growths on the uterus. Hundreds of thousands of women undergo a hysterectomy (surgical removal of the uterus) or myomectomy (fibroid removal surgery). In tens of thousands of women, surgeons use a tool called a power morcellator to lance the uterus into tiny pieces, which are then vacuumed out through a tube.
Fibroids and Cancer
Fibroids are sometimes cancerous. Some one in 350 women who undergo a hysterectomy to remove fibroids has uterine sarcoma; roughly one in 500 has an aggressive form of cancer called leiomyosarcoma (LMS).
A morcellator used without a protective surgical bag can leave tissue bits behind. When that tissue contains cancerous cells, the power morcellator can spread cancer throughout the pelvis, abdomen and elsewhere. Surgeons can reduce the risk of spreading cancer by using bags; but many surgeons don’t use the flimsy, awkward bags.
FDA Warning for Hysterectomy Cancer Risk
In April 2014, the U.S. FDA published a Safety Warning which recommended morcellators not be used in the treatment of uterine fibroids or hysterectomies. The FDA wrote:
“If laparoscopic power morcellation is performed in women with unsuspected uterine sarcoma, there is a risk that the procedure will spread the cancerous tissue within the abdomen and pelvis, significantly worsening the patient’s likelihood of long-term survival. For this reason, and because there is no reliable method for predicting whether a woman with fibroids may have a uterine sarcoma, the FDA discourages the use of laparoscopic power morcellation during hysterectomy or myomectomy for uterine fibroids.”
Many women have filed lawsuits alleging they were never warned about the risks of cancer from a hysterectomy using a power morcellator. Many also say they were never informed of safer alternatives.
Morcellators have been promoted as a means of reducing pain, speeding recovery, and cutting down scarring. These promotional points may be valid when compared with open abdominal surgery, but morcellator benefits are less clear in comparison with alternative, minimally-invasive laparoscopic procedures.
According to FDA, alternatives include:
- Surgical hysterectomy performed vaginally or abdominally
- Laparoscopic hysterectomy or myomectomy that does not involve morcellation.
- Catheter-based blocking of the uterine artery.
- High-intensity focused ultrasound.
- Drug therapy.